A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors

Trial Profile

A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2007

At a glance

  • Drugs Cevipabulin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 11 Jan 2007 Status change
    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top